Bio Blast Pharma Ltd (ORPN) was initiated at Oppenheimer with a ‘Outperform’ and price target of $32 in a research report issued to clients on Monday. The firm‘s target price suggests a potential upside of about 317% from the company’s previous close. Bio Blast Pharma increased 1.19% to close at $7.68 on August 22. Oppenheimer […] View the full post at: Bio Blast Pharma (ORPN) Raised At Oppenheimer No related posts.